StreetAlpha
13F holdings · Q3 2026

Krensavage Asset Management

New York, NY · files as Krensavage Asset Management, LLC
Know the moment Krensavage Asset Management filesYou follow Krensavage Asset Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1609251

Krensavage Asset Management reported 20 stocks worth $265M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are JAZZ (14.6%), ENTA (14.2%) and UTHR (13.5%). Compared with Q2 2026, the fund opened new positions in ANIP, ACAD and ZTS, added to RARE, SUPN and SNY, trimmed UTHR, EXEL and EOLS and sold out of REGN.

Latest filing: what Krensavage Asset Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
3 new4 added3 trimmed1 sold outBought about $21.5M · sold about $10.3M
New 3
Added 4
Trimmed 3
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$265M+0.8% vs last quarter
Stocks held203 new · 1 sold out
Top 5 weight61.7%very concentrated
Turnover12%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
JAZZ
Jazz Pharmaceuticals PLC
$38.9M14.6%168KNo change8 of 8
2
ENTA
Enanta Pharmaceuticals Inc
$37.8M14.2%2.9MNo change8 of 8
3
UTHR
United Therapeutics Corp Del
$35.9M13.5%66K−3,000 (−4%)8 of 8
4
BMRN
Biomarin Pharmaceutical Inc
$31.5M11.9%525KNo change5 of 8
5
ABT
Abbott Labs
$19.8M7.5%200KNo change3 of 8
6
EXEL
Exelixis Inc
$17.5M6.6%299K−71K (−19%)8 of 8
7
RARE
Ultragenyx Pharmaceutical in
$17.1M6.5%1.1M+750K (+192%)4 of 8
8
SUPN
Supernus Pharmaceuticals Inc
$15.1M5.7%351K+70K (+25%)7 of 8
9
SNY
Sanofi
$13.8M5.2%334K+10K (+3%)8 of 8
10
EMBC
Embecta Corp
$6.4M2.4%1.1MNo change3 of 8
🔒 10 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
REGN
Regeneron Pharmaceutical
$3.7M6,000

Reported value

last 8 quarters
$169MQ4 '24
$181MQ1 '25
$189MQ2 '25
$235MQ3 '25
$283MQ4 '25
$256MQ1 '26
$263MQ2 '26
$265MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Krensavage Asset Management 13F FAQ

What does Krensavage Asset Management own?

Krensavage Asset Management reported 20 stocks worth $265M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are JAZZ (14.6%), ENTA (14.2%) and UTHR (13.5%). The table above lists every position in the filing (the top 10 without an account).

What did Krensavage Asset Management buy and sell in Q3 2026?

Compared with Q2 2026: 3 new positions, 4 added to, 3 trimmed and 1 sold out. New positions include ANIP, ACAD and ZTS. It sold all of REGN.

When will Krensavage Asset Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Krensavage Asset Management's portfolio worth?

The Q3 2026 filing reports $265M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.